Objectives-Defective endothelial regeneration predisposes to adverse arterial remodeling and is thought to contribute to cardiovascular disease in type 2 diabetes mellitus. We recently demonstrated that the type 1 insulin-like growth factor receptor (IGF1R) is a negative regulator of insulin sensitivity and nitric oxide bioavailability. In this report, we examined partial deletion of the IGF1R as a potential strategy to enhance endothelial repair. Approach and Results-We assessed endothelial regeneration after wire injury in mice and abundance and function of angiogenic progenitor cells in mice with haploinsufficiency of the IGF1R (IGF1R +/− ). Endothelial regeneration after arterial injury was accelerated in IGF1R +/− mice. Although the yield of angiogenic progenitor cells was lower in IGF1R +/− mice, these angiogenic progenitor cells displayed enhanced adhesion, increased secretion of insulin-like growth factor-1, and enhanced angiogenic capacity. To examine the relevance of IGF1R manipulation to cell-based therapy, we transfused IGF1R +/− bone marrow-derived CD117 + cells into wild-type mice. IGF1R +/− cells accelerated endothelial regeneration after arterial injury compared with wild-type cells and did not alter atherosclerotic lesion formation. Conclusions-Haploinsufficiency of the IGF1R is associated with accelerated endothelial regeneration in vivo and enhanced tube forming and adhesive potential of angiogenic progenitor cells in vitro. Partial deletion of IGF1R in transfused bone marrow-derived CD117 + cells enhanced their capacity to promote endothelial regeneration without altering atherosclerosis. Our data suggest that manipulation of the IGF1R could be exploited as novel therapeutic approach to enhance repair of the arterial wall after injury. (Arterioscler Thromb Vasc Biol. 2014;34:2051-2058.)
T ype 2 diabetes mellitus is a disorder of cell growth and metabolism leading to a portfolio of chronic disorders of human health dominated by atherosclerosis-related diseases, such as myocardial infarction, stroke, and peripheral arterial disease. As a result, individuals with type 2 diabetes mellitus experience cardiovascular event rates clinically manifest 15 years earlier than in patients without diabetes mellitus. 1 Effective endothelial repair following structural or functional damage to the endothelium is critical to prevent adverse arterial remodeling, thrombosis, and atherosclerosis. 2 Recent studies support a prominent role for impairment of nitric oxide (NO)-dependent endothelial cell repair/replacement in diabetes mellitus-related vascular disease. 3, 4 Indeed, insulin resistance, the primary metabolic disturbance underpinning type 2 diabetes mellitus, is associated with delayed endothelial repair in the absence of overt glycemia. 4 We recently demonstrated that the type 1 insulin-like growth factor receptor (IGF1R), which acts as the principal tyrosine kinase receptor delivering cues for cellular and whole organism growth, is a negative regulator of NO bioavailability and insulin sensitivity in the endothelium. 5 In mice with haploinsufficiency of the IGF1R, we observed a phenotype of enhanced whole-body insulin sensitivity, enhanced insulin-stimulated phosphorylation of endothelial nitric oxide synthase (eNOS), and increased basal NO generation. 5 In the present report, we examine the effect of partial deletion of the IGF1R on vascular regeneration in this model and investigate whether manipulation of IGF1R abundance could be a strategy to refine cell-based therapy to augment endothelial repair.
Materials and Methods
Materials and Methods are available in the online-only Supplement.
Results

Effect of Partial IGF1R Deletion on Endothelial Regeneration After Arterial Injury
To investigate the effects of partial deletion of IGF1Rs on endothelial regeneration, we subjected IGF1R +/− and wildtype (WT) mice to femoral artery endothelium-denuding wire injury. Femoral arteries were harvested ay days 0, 4, and 7 and the area of endothelial regeneration quantified by Evans blue staining. Wire injury induced immediate and complete denudation of endothelium ( Figure 1A and 1B) . Four days after injury, IGF1R +/− mice displayed significantly enhanced reendothelialization compared with WT littermates ( Figure 1A and 1B). Regenerated area was similar in IGF1R +/− and WT mice by day 7 (Figure 1A and 1B). Serum concentration of insulin-like growth factor (IGF)-1 was similar in IGF1R +/− and WT mice ( Figure 1C ).
Quantification of Angiogenic Progenitor Cells
To investigate whether the accelerated endothelial repair in IGF1R +/− mice was contingent on increased abundance of endothelial progenitors, we quantified circulating Sca-1 + / Flk-1 + progenitor cells and the yield of angiogenic progenitor cells (APCs) from mononuclear cells in IGF1R +/− and WT mice. Sca-1 + /Flk-1 + cells were similar in abundance in IGF1R +/− mice compared with WT littermates (Figure 2A ). Mobilization of progenitor cells from the bone marrow niche in response to proangiogenic cytokines is a prerequisite for effective endothelial repair. 6 Systemic administration of vascular endothelial growth factor increased circulating numbers of Sca-1 + /Flk-1 + cells in both groups of mice ( Figure 2B ). We found no significant difference in APC mobilization following vascular endothelial growth factor administration in IGF1R +/− mice compared with WT littermates ( Figure 2C ). We expanded mononuclear cells derived from peripheral blood, spleen, and bone marrow and counted cells displaying typical properties (eg, uptake of acetylated low-density lipoproteins and binding of Ulex lectin) after 7 days of culture as APCs ( Figure 2D ). The yield of APCs from blood and bone marrow was significantly lower in IGF1R +/− mice compared with WT; no difference between mice was found in the yield of spleen-derived APCs ( Figure 2E ). The size and density of APCs, assessed by flow cytometry, was similar in WT and IGF1R +/− mice ( Figure  IA and IB in the online-only Data Supplement). Expression of the leukocyte marker CD11b and the integrin chain CD49e (which is abundantly expressed on monocytes) were similar in APCs from WT and IGF1R +/− mice ( Figure IC and ID in the online-only Data Supplement). APCs from both genotypes expressed the markers CD68 and Factor XIII-A ( Figure IE in the online-only Data Supplement) in keeping with the monocytic origin of these cells. 7
Adhesion Assay
As adhesion of circulating cells to the damaged vessel wall is a critical step in progenitor cell-mediated vascular repair, we examined the capacity of APCs to adhere to the extracellular matrix glycoprotein protein fibronectin in vitro. APCs from IGF1R +/− mice showed significantly enhanced adhesion to fibronectin compared with WT APC ( Figure 3A ). Incubation of APCs with the NO synthase inhibitor N G -monomethyl-Larginine did not modify adhesion of WT APCs but significantly inhibited adhesion of IGF1R +/− APCs to control levels ( Figure 3A) . 
Tube-Forming Assay
To evaluate the effect of partial IGF1R deletion on the angiogenic potential of APCs, we performed an in vitro angiogenesis assay using conditioned media from APCs from IGF1R +/− and WT mice. As shown in Figure 3B and 3C, we demonstrated a significant increase in endothelial tube formation when human umbilical vein endothelial cells were cultured with conditioned medium from IGF1R +/− APCs compared with medium from WT APCs. We then measured secretion of angiogenic cytokines by APCs of both genotypes. We observed a significant increase in concentration of IGF-1 in conditioned medium of IGF1R +/− APCs compared with WT APCs ( Figure 3D ). The concentrations of vascular endothelial growth factor and hepatocyte growth factor were similar in conditioned media from IGF1R +/− and WT APCs ( Figure 3E -3F). Concentrations of stromal cell-derived factor-1 and granulocyte colony-stimulating factor were below the limits of detection (not shown).
Expression of IGF1R, Insulin Receptor, and eNOS in APC
Real-time reverse-transcription polymerase chain reaction demonstrated robust expression of the truncated Igfr1 allele with deletion of exon 3 (encoding a nonfunctional receptor protein) in APCs from IGF1R +/− mice as expected ( Figure 4A ). Expression of insulin receptor mRNA was significantly increased in APCs from IGF1R +/− mice ( Figure 4B ). We found no difference in expression of eNOS mRNA in APC from IGF1R +/− mice compared with WT mice ( Figure 4C ). eNOS protein expression was similarly unchanged in mononuclear cells derived from bone marrow of IGF1R +/− mice compared with that from WT mice ( Figure 4D ). However, eNOS 1177 Serphosphorylation was significantly higher in cells derived from IGF1R +/− mice compared with WT mice ( Figure 4D ).
Aortic Ring Angiogenesis Assay
Endothelial repair is thought to be mediated by an orchestrated response of both circulating APCs and proliferation of native vascular endothelial cells. To investigate whether partial deletion of IGF1R impacts on endothelial cell vascular sprouting in the absence of circulating progenitor cells, we performed an in vitro angiogenesis assay in aortic rings. Angiogenic sprouting did not differ significantly in aortic rings harvested from IGF1R +/− mice and WT littermates ( Figure II in the onlineonly Data Supplement).
Effect of Pharmacology IGF1R Inhibition on Endothelial Regeneration After Arterial Injury
To determine whether the enhanced endothelial repair mediated by genetic partial deletion of IGF1R could be replicated by pharmacological inhibition of IGF1R, we performed further arterial injury experiments in WT mice treated with PQ401, which blocks signal transduction by inhibiting IGF1R autophosphorylation. 8 Administration of PQ401 did not 
Effect of Partial Deletion of IGF1R in Transfused CD117 + Cells on Endothelial Regeneration
To evaluate whether enhanced endothelial repair associated with IGF1R downregulation is contingent on changes in the vessel wall or in progenitor cells per se, we performed further injury experiments followed by infusion of bone marrow-derived CD117 + (c-kit + ) cells, which we have previously shown to be effective in enhancing arterial endothelial regeneration. 4 Splenectomized WT mice were infused with WT or IGF1R +/− bone marrow-derived CD117 + (c-kit + ) cells or saline after femoral artery injury. Re-endothelialization was significantly enhanced by infusion of IGF1R +/− CD117 + bone marrow-derived cells when compared with infusion of WT cells or cell-free saline ( Figure 5A and 5B). To investigate whether transfused CD117 + cells incorporate into the neoendothelium, we repeated the injury experiments in WT mice transfused with CellTracker-Red-labeled CD117 + cells. Labeling with CellTracker-Red did not alter the regenerative capacity of the cells: endothelial regeneration remained enhanced after transfusion of cells with partial deletion of IGF1R ( Figure 5C and 5D). At day 4 following arterial injury, CellTracker + cells were detected only rarely in the neoendothelium (in 1 of 4 mice receiving WT cells and 1 of 4 mice receiving IGF1R +/− cells; Figure 5E ).
Effect of Partial Deletion of IGF1R in Transfused CD117 + Cells on Atherosclerosis
Because there are conflicting data on the effects of transfusion of bone marrow-derived mononuclear cells on atherosclerosis, with both increased 9,10 and reduced 11, 12 atherosclerotic plaques reported, we performed further experiments to exclude the possibility that partial IGF1R deletion in transfused CD117 + cells could be proatherosclerotic. We quantified atherosclerotic lesion formation in ApoE −/− mice subjected to adventitial carotid artery cuff placement after transfusion of IGF1R +/− or WT CD117 + bone marrow cells. We confirmed that partial IGF1R deletion in transfused cells did not alter atherosclerotic lesion formation ( Figure 6A and 6B). To determine whether transfused cells incorporated into plaques, we repeated the experiment using CD117 + cells labeled with CellTracker. At 4 days after transfusion, very few CellTracker + cells were observed in cuffed carotid arteries (scant CellTracker + staining was seen in 2 of 3 mice receiving WT cells and 1 of 4 mice receiving IGF1R +/− cells; Figure 6D and 6E). When present, CellTracker + cells were seen in both the endothelium and adventitia ( Figure 6D and 6E) . 
Discussion
This study builds on our recent reports highlighting IGF1R abundance as a modulator of endothelial NO bioavailability 5, 13 by demonstrating a critical role of the IGF1R in vascular repair. First, we observed that endothelial regeneration is significantly accelerated in IGF1R-deficient mice following denuding wire injury. Second, APCs derived from IGF1R-deficient mice displayed enhanced angiogenic properties in vitro. IGF1R +/− APCs exhibited increased adhesion to extracellular matrix, an effect blocked by inhibition of NO synthase. APCs from IGF1R +/− mice also demonstrated increased secretion of IGF-1 into the medium and greater capacity to promote endothelial tube formation. Third, infusion of CD117 + bone marrow-derived cells deficient in IGF1R into WT mice after denuding injury accelerated healing in comparison with infusion of WT APCs, but did not alter atherosclerotic lesion formation. Collectively, these findings support a novel role for the IGF1R in vascular regeneration. Recent large-scale clinical trials have challenged conventional thinking about therapeutic strategies aiming to reduce the complications of atherosclerosis in patients with type 2 diabetes mellitus. 14 These studies demonstrated that intensive lowering of blood glucose [15] [16] [17] fails to improve cardiovascular mortality in individuals suffering from type 2 diabetes mellitus. We have shown that despite contemporary secondary prevention therapies, mortality after an acute myocardial infarction in patients with type 2 diabetes mellitus has not improved over the last 10 years, in contrast to the enhanced outcomes enjoyed by patients without type 2 diabetes mellitus. 18 Collectively, these data highlight the fundamental importance of identifying novel approaches to prevent/retard cardiovascular complications in patients with type 2 diabetes mellitus.
Recently, new mechanistic insights into the regulation of endothelial function in the context of metabolic disorders have begun to emerge. Critically, we have shown that the IGF1R can reduce NO bioavailability by interacting with insulin receptors to form insulin-resistant hybrid receptors. 5, 19 An increase in hybrid receptors is a hallmark of type 2 diabetes mellitus and obesity. 20 Many aspects of the diabetic phenotype have been shown to contribute to the formation of hybrids, suggesting that their formation is not just a random process. We demonstrated that downregulation of IGF1R at the wholebody level, or selectively in the endothelium, confers both enhanced insulin sensitivity and endothelial NO generation. 5 These data raise the possibility that modulation of IGF1R abundance could be of pathological and potential therapeutic importance in vascular remodeling and disease.
Effective endothelial repair in response to mechanical or biochemical injury has been implicated in preventing adverse vascular remodeling and is thought to mitigate against a range of pathologies, including atherosclerosis, 21 restenosis, 22 stent thrombosis 23 , and bypass graft failure. 24 Recruitment of circulating progenitor cells to sites of injury is central to the repair process. 2 IGF-1 is recognized to increase the circulating abundance and enhance the function of endothelial progenitor cells via a mechanism involving phosphoinositide-3-kinase/Aktmediated phosphorylation of eNOS. 25 Insulin-invoked clonal expansion of endothelial progenitor cell colony-forming units in vitro is also thought to be transduced by the IGF1R rather than the insulin receptor. 26 However, the effects of genetic modulation of IGF1R abundance in progenitor cells and consequences for endothelial repair have not previously been subjected to scrutiny.
In the present study, we have clearly demonstrated that reducing IGF1R at a whole-body level accelerates regeneration of the endothelium after mechanical injury. This observation contrasts with our recent findings in mice with haploinsufficiency of the insulin receptor in which endothelial regeneration was compromised 4 and implies divergent functional consequences of downregulation of the 2 tyrosine kinase receptors on vascular repair. We did not uncover any differences in angiogenic sprouting between vessels from IGF1R +/− and WT mice in vitro, suggesting that alterations in circulating progenitor cells rather than native endothelial cells likely contributed to the enhanced endothelial regeneration observed in vivo. We observed significant reductions in bone marrow-derived and circulating APCs in IGF1R +/− mice. Although at first this seems discordant with the accelerated repair observed in IGF1R +/− mice, it is possible that reduced bone marrow stores and circulating abundance of APCs in IGF1R +/− mice arise as a compensatory response to their enhanced functionality. It is also possible that there is reduced basal endothelial damage in IGF1R +/− mice in keeping with their greater longevity. 27 The contribution of APCs to endothelial regeneration is dependent not only on their efficient mobilization in to the circulation but also by their attachment to the damaged vascular wall and favorable functional characteristics. Direct evidence that APCs may contribute to endothelial regeneration has emerged from our own studies 4 and those of other laboratories. 28, 29 In keeping with others reports, we demonstrated that APCs display markers of monocytic origin which is in accordance with the accepted paradigm that these cells facilitate vascular repair by secreting proangiogenic cytokines, rather than expanding to regenerate damaged endothelium per se. 30 In vitro studies described here are consistent with this paradigm, as we demonstrated that IGF1R-deficient APCs were more adherent to the matrix protein fibronectin and enhanced formation of tubular networks of human umbilical vein endothelial cells more than comparative WT cells. Intriguingly, we found secretion of IGF-1 in to medium was increased in IGF1R +/− cells in comparison with WT cells. IGF-1 exerts potent proangiogenic effects on endothelial cells, 31 which may explain the increased tube formation we observed in vitro. It is less clear whether increased IGF-1 secretion by APCs could explain the enhanced endothelial regeneration occurring in vivo when IGF1R abundance is also reduced. However, we previously observed that vascular responses to IGF-1 were diminished, but not abrogated in IGF1R +/− mice, 5 suggesting that endothelial cells remain responsive to IGF-1. Nevertheless, enhanced functionality of IGF1R +/− APCs may be permissive of their lower abundance in normal vascular homeostasis and may facilitate more expeditious repair in the context of vascular injury. At the mechanistic level, although APC function is regulated by a range of factors, bioavailability of NO plays a key role. 32 As our in vitro experiments were performed in the absence of exogenous IGF-1, we postulate that the enhanced functions of IGF1R +/− APCs we observed are secondary to increased NO bioavailability facilitated by reduced IGF1R abundance rather than altered responses to IGF-1 per se. This is in keeping with our previous demonstration that reduced IGF1R abundance enhances NO generation and insulin sensitivity by altering IGF1R-insulin receptor stoichiometry and hybrid receptor formation. 5 Our demonstration here that enhanced adhesion of IGF1R +/− APCs is abrogated by NO synthase inhibition and our finding of increased serine phosphorylation of eNOS in APCs from IGF1R +/− mice, despite similar circulating IGF-1 concentrations, are consistent with this contention. It is also noteworthy that inhibition of IGF1R with monoclonal antibodies, which would not be expected to alter IGFR-insulin receptor stoichiometry, has been shown to reduce the migratory and angiogenic capacity of APCs in vitro, 25 which contrasts with our finding of enhanced APC function in response to genetic partial deletion of IGFRs.
The enhanced repair observed following partial IGF1R deletion in vivo was not replicated by pharmacological IGF1R inhibition with PQ401. The chronicity of IGF1R suppression achieved by genetic IGF1R deletion limits direct comparison with acute pharmacological IGF1R inhibition. It is possible, however, that the pharmacological strategy proved ineffective because inhibition of IGFR autophosphorylation by PQ401 would not be expected to modulate IGF1R-insulin receptor stoichiometry and hybrid receptor formation, with the consequent enhancement of insulin signaling and NO bioavailability.
Cell-based therapies aimed at enhancing vascular repair represent a novel nonpharmacological approach to treat and prevent diabetes mellitus-related cardiovascular disease. 33 Although some commentators have drawn into question the contribution of progenitor cells to normal vascular homeostasis, 34, 35 our demonstration here that infusion of cells enhances regeneration adds to the evidence that such cells offer therapeutic potential. Bone marrow cells enriched for the stem cell marker CD117 (c-kit) represent a promising population to augment vascular repair, and we have previously shown these cells to accelerate endothelial regeneration in the context of insulin resistance. 4 Here, by demonstrating that downregulating the IGF1R in infused CD117 + cells enhances their reparative capacity, we raise the intriguing possibility that modulating IGF1R abundance could be a strategy to circumvent the progenitor cells dysfunction which currently limits the utility of cell-based regenerative therapy in diabetes mellitus.
Although infused unselected mononuclear cells and APCs are known to incorporate into the vessel wall, 36 the homing and incorporation of CD117 + cells remains underexplored. Here, we observed robust positive effects of infused CD117 + cells on endothelial regeneration, despite apparently detecting only rare incorporation of infused cells into the injured vessel wall at 4 days after injury. As little is known about the kinetics and survival of infused CD117 + cells, we cannot exclude the possibility that the cells incorporated early after infusion but failed to persist >4 days. It is clear that infused CD117 + cells do not directly contribute to endothelial coverage per se, and it is likely that they augment the formation of the neoendothelium by paracrine or systemic effects of secreted angiogenic factors on native endothelial cells.
Enthusiasm for cell-based therapy may be tempered by reports that mononuclear cell infusion can accelerate and diminish atherosclerosis. [9] [10] [11] [12] Here, we were reassured that partial deletion of IGF1R in CD117+ cells infused in to ApoE −/− mice did not modify atherosclerotic lesion formation, suggesting that this strategy could safely be exploited for therapeutic use to accelerate re-endothelialization. 
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